X

Nadine McGrath

Nadine is a Brisbane-based journalist with a keen interest in financial markets and the economy. Her media career kicked off as a rural reporter with WIN Television progressing to News Ltd and Australian Associated Press. She’s also worked on the other side in public relations. Nadine has a keen interest in seeking out and telling stories from ASX-listed small and midcaps across a range of sectors. In her spare time (!) she’s mostly bossing her three teenagers around and if that all becomes too much she’ll head out for a run or hit the yoga mat.

ScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reports

ASX health stocks rise 1.4% in the past five days in line with broader markets as Imricor (ASX:IMR) prepares for…

ASX Tech April Winners: Sector falls ~4% in month as rich-lister increases stake in Vinyl Group

The ASX tech sector fell 3.87% in April 2024 as economic and geopolitical uncertainty played on markets but remains up…

ASX Quarterly Health Wrap: Which companies are making progress in clinical trials?

Several ASX health stocks made strides with clinical trials during the last quarter including Optiscan (ASX:OIL).

ASX April Winners: The best 50 stocks as inflation and Middle East tension cloud markets

The S&P/ASX 200 fell 2.94% in April as all Australian equity indexes fell except Emerging Companies in a tough month…

ASX Quarterly Tech Wrap: Altech advances CERENERGY batteries, iCandy achieves record cash receipts

Altech (ASX:ATC) progressed its ambition of becoming a significant supplier into the grid energy storage market during the last quarter.

ASX medtechs poised to transform healthcare with upcoming catalysts in 2024 – Part 2

In 2024 several ASX medtech companies have upcoming catalysts as they strive to innovate healthcare including EBR Systems (ASX:EBR).

ASX Quarterly Health Wrap: LTR Pharma firms up trial recruitment as Dimerix achieves key milestone

Several ASX biotech companies have made strong progress during the last quarter including LTR Pharma (ASX:LTP).

ASX medtechs poised to transform healthcare with upcoming catalysts in 2024 – Part 1

As cutting-edge technology and healthcare converge, companies within the sector are pioneering solutions that revolutionise diagnosis, treatment and patient care.

Aroa Biosurgery to target US$300 million trauma market with Myriad products

Aroa Biosurgery (ASX:ARX) focusing on trauma markets, which based on estimates, has a TAM in the US of ~US$300 million.

Making resources sector WISER through greater gender diversity

WISER is a new network of women in renewable energy, mining and energy storage in Queensland run by QEM's Jo…

Top 10 at 10: Base Resources soars on acquisition deal with US-based Energy Fuels

Base Resources (ASX:BSE) has announced a proposed 100% acquisition by NYSE-listed uranium and critical minerals producer, Energy Fuels.

ScoPo’s Powerplays: Nowhere to hide as ASX health stocks tumble in broader selloff

ASX health stocks fall in past five days in line with broader markets as ResMed (ASX:RMD) feels more heat from…

Sure the Magnificent 7 are great… but have you seen the ‘Global Glorious 10’?

Saxo Markets says investors should look beyond Magnificent 7 for greater diversity and has come up with the Global Glorious…

Which ASX companies are resurrecting abandoned drugs? Part 3

Paradigm Pharmaceuticals (ASX:PAR) has identified the potential of PPS, an FDA-approved drug to treat osteoarthritis.

Which ASX companies are resurrecting abandoned drugs? Part 2

ASX companies are cleverly resurrecting and repurposing abandoned drugs including LTR Pharma (ASX:LTR) with their erectile dysfunction spray.

Which ASX companies are resurrecting abandoned drugs? Part 1

Race Oncology (ASX:RAC) is among ASX-listed biotechs resurrecting or repurposing abandoned or underutilised drugs.

ScoPo’s (actually Wilkie’s) Powerplays: Blinklab soars 32.5% in first healthcare IPO of 2024

Blinklab (ASX:BB1) has became the first healthcare IPO so far of 2024 listing on April 4 with an impressive 32.5%…